In 2008, Zhang et al. found that SIRT1 was localized to the nucleus and cytoplasm of surface epithelial cells in OV2008 and C13 ovarian cancers and that it stimulated tumor cell migration through the deacetylation of cortical actin, supporting its potential as a new target for HDAC inhibitor-based therapies [62]. Here, SIRT1 is linked to ovarian carcinoma.